Eribulin in Advanced Solitary Fibrous Tumor

Exclusion Criteria

• •1. Naïve patients
• •2. More than 2 lines of anticancer treatment
• •3. Previous treatment with any other anti-cancer investigational or not investigational agents within 21 days of first day of study drug dosing,
• •4. Previous treatment with radiation therapy within 14 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents previously administered
• •5. Previous radiotherapy to 25% of the bone marrow
• •6. Major surgery within 21 days prior to study entry
• •7. Other primary malignancy with \<5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
• •8. Pregnancy or breast feeding
• •9. Cardiovascular diseases resulting in a New York Heart Association Functional Status \>2 . Medical history of a myocardial infarction \< 6 months prior to initiation of study treatment. Unstable angina or myocardial infarction within 6 months of enrolment, Serious and potentially life-threatening arrhythmia
• •10. Subjects with a high probability of Long QT Syndrome or corrected QT interval prolongation of more than or equal to 501 msec , following correction of any electrolyte imbalance
• •11. Medical history of arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
• •12. Known history of human immunodeficiency virus infection
• •13. Active or chronic hepatitis B or C requiring treatment with antiviral therapy
• •14. Medical history of hemorrhage or a bleeding event ≥ Grade 3 according Common Terminology Criteria for Adverse Events (CTCAE) within 4 weeks prior to the initiation of study treatment
• •15. Evidence of any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
• •16. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
• •17. Subjects who have not recovered from acute toxicities as a result of prior anti-cancer therapy to ≤ Grade 1 of CTCAE, except for peripheral neuropathy and alopecia.
• •18. Pre-existing peripheral neuropathy \> CTCAE Grade 2.
• •19. Expected non-compliance to medical regimens
• •20. Subjects with known central nervous system metastases